Table 1.
pSS patients (N = 42) | |
---|---|
Age (years) | 62 (51; 68) |
Sex (males/females) | 2/40 |
Disease duration (years) | 16 (7; 23) |
Current/prior/never smokers (%) | 20/41/39 |
Anti-SS-A antibody seropositives (%) | 76 |
Anti-SS-B antibody seropositives (%) | 48 |
ANA seropositives (%) | 79 |
RF seropositives (%) | 52 |
IgG (g/L) | 13.1 (10.0; 17.1) |
Complement component 3 (g/L) | 1.00 (0.89; 1.15) |
Complement component 4 (g/L) | 0.16 (0.12; 0.21) |
Lip biopsy—focus score ≥ 1 (N positives/N studied (%)) | 28/33 (85) |
ESSDAI total score | 6 (1; 12) |
ESSPRI total score | 6 (5; 8) |
Fecal calprotectin (μg/g) | 38 (20; 123) |
Irritable bowel syndrome-like symptoms (%) | 42 |
Using proton pump inhibitors (%) | 36 |
Using NSAIDs (%) | 38 |
Using glucocorticoids (%) | 36 |
> 5 mg prednisolone daily | 7 |
5 mg prednisolone daily | 24 |
< 5 mg prednisolone daily | 5 |
Using anti-malarials (%) | 29 |
Using other DMARDs (%) | 2 |
Demographic and clinical characteristics of the patients with primary Sjögren’s syndrome (pSS). Results presented as median (interquartile range) or percentage of subjects
DMARD disease-modifying anti-rheumatic drug, ESSDAI EULAR Sjögren’s Syndrome Disease Activity Index, ESSPRI EULAR Sjögren’s Syndrome Patient Reported Index, EULAR European League Against Rheumatism, NSAID nonsteroidal anti-inflammatory drug, ANA antinuclear antibodies, RF rheumatoid factor